A New Treatment for Rheumatoid Arthritis - InfoBarrel

A New Treatment for Rheumatoid Arthritis?A German biotechnology company is developing an antibody which could revolutionise strategy to rheumatism. Munich based Morphosys, are developing an antibody that's targeting at blocking a protein called http://rocko.bravesites.com/entries/general/neostem-s-additional-stem-cell-treatment-percentage- granulocyte macrophage colony stimulating factor (GM-CSF).The idea of blocking GM-CSF is because it's a growth aspect in producing white blood cells, that are seen in abundance inside the inflamed joints of rheumatism sufferers.What is Rheumatoid Arthritis?It is really a disorder in the immune system that produces your body to be struggling to differentiate between foreign antigens and healthy cells. As a consequence one's body produces a surplus flow of white blood cells (as a way to fight what it really mistakenly identifies as being a foreign agent) which ultimately, cause inflammation of the joints. This is not only painful, but sometimes cause joint deformation.GM-CSF is a hematopoietic cytokine and is also naturally made by one's body's body's defence mechanism. It is made by B cells, Tcells, macrophages, mast cells, endothelial cells and fibroblasts. It is human specific and, therefore a firm like Morphosys (whose platform produces human antibodies) has an edge in creating a blocker correctly.GM-CSF has a wide and diverse usage inside bodies defense mechanisms and may, therefore, be utilized across a number of indications.A New Treatment for Multiple Sclerosis in addition to Rheumatoid Arthritis?Morphosys MOR103 has developed to block GM-CSF which is currently inside a phase 1b/2a trial for rheumatism. In fact, the organization are http://www.viewdocsonline.com/document/ydtlkm extremely encouraged with this trial they have decided to take MOR103 into a phase 1b trial in multiple sclerosis inside the second half of 2011. The possibility exists for MOR103 to become taken into development for asthma too. This would most likely be by Morphosys as they own http://biotech00.webgarden.com/sections/blog/older-overseer-state-matters the exclusive entry to rights in the using developing GM-CSF for anti-inflammatory diseases in the United States.With regards the continued Phase 1b/2a clinical study for rheumatoid arthritis symptoms patients, the end result are likely to be in 2012.These are exciting developments and auger well for producing new treatments for rheumatoid arthritis sufferers and multiple sclerosis patients.